


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (I):



(I)

wherein:

W and Y are independently is a straight or branched chain C₁₋₅ alkylene group optionally containing one double bond[,] or one triple bond or carbonyl, wherein said C₁₋₅ alkylene group is optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl, C₁₋₄ haloalkyl or C₁₋₄ alkoxy;

Y is a straight or branched chain C₁₋₅ alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C₁₋₅ alkylene group is optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl, C₁₋₄ haloalkyl or C₁₋₄ alkoxy;

X is -NR₃C(O)-, -C(O)NR₃, -NR₃S(O)₂-, -S(O)₂NR₃-, -NR₃C(O)NR₄-, -NR₃C(O)O-, -OC(O)NR₃-, -NR₃-, -C(O)-, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or -S(O)₂-;

R₃ and R₄ are independently H, C₁₋₄ alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

R₁ is H, ~~hydroxyl~~, halogen, C₁₋₄ alkyl or C₁₋₄ haloalkyl;

R₂ is H or C₁₋₈ alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that:

i) ~~when both R₁ and R₂ are H then [W]_n-X-[Y]_m-Z together is not CO₂H, C(O)-C₆H₄-p-O-C₈H₁₇, OCH₂CH₃, OH, CH₂CH₂CH₂CH₂CO₂H, CH₂CH₂CH₂CO₂H, CH₂CO₂H and CH₂CH₂CO₂H;~~

ii) ~~when R₁ is CH₃ and R₂ is H then [W]_n-X-[Y]_m-Z together is not CH₂CO₂H, C(O)CH=CH-C₆H₅, C(O)-C₆H₄-p-OCH₃, CO₂H, C(O)CH₃, C(O)-C₆H₄-o-CH₃, C(O)-C₆H₄-o-Br, C(O)-C₆H₄-o-Cl, and C(O)-C₆H₅;~~

iii) ~~when R₁ is Br and R₂ is H then [W]_n-X-[Y]_m-Z together is not CO₂H;~~

iv) ~~when R₁ is OH and R₂ is H then [W]_n-X-[Y]_m-Z together is not CO₂H;~~

v) when R₁ is H and R₂ is CH₃ then [W]_n-X-[Y]_m-Z together is not 2,6-dichloro-4-trifluoromethylphenoxy, C(O)NH-C₆H₄-p-OCH₂CH₃, NHC(O)CH(CH₃)₂, SCH₃, C(O)-C₆H₄-p-O-C₈H₁₇, SCH₂CH₃, C(O)NHC₆H₅, CH(OCH₃)₂, CH₂OC(O)CH₃, CO₂H, CO₂CH₃, C(O)-C₆H₄-p-NO₂, C(O)-C₆H₅, CH₂CH₂CO₂CH₃, CH₂CH₂CH₂CH₂CO₂CH₃, CH₂CH₂CH₂CO₂CH₃ and CH₂CO₂CH₃;

vi) ~~when R₁ is OH and R₂ is CH₃ then [W]_n-X-[Y]_m-Z together is not CH₂OCH₂C₆H₅, CH₂OCH(CH₃)₂ and CH₂OH;~~

vii) ~~when R₂ is CH₃ then:~~

~~R₁ is not CH₃ and [W]_n-X-[Y]_m-Z together is not 2,6-dichloro-4-trifluoromethylphenoxy;~~

~~R₁ is not I and [W]_n-X-[Y]_m-Z together is not CO₂C(CH₃)₃;~~

~~R₁ is not C(CH₃)₃ and [W]_n-X-[Y]_m-Z together is not formyl;~~

~~R₁ is not Br and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2CH_2CH_3$;~~

~~and~~

~~R₁ is not $CH_2CH_2CH_2CH_3$ and $-[W]_n-X-[Y]_m-Z$ together is not formyl;~~

viii) when R₁ is H and R₂ is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH_2SCH_2CH_3$, $OCH_2CH_2CH=CH_2$, $CH_2CH_2CH_2OH$, CH_2CH_2CHO , $CO_2CH_2CH_3$, OCH_3 , $C(O)CH_2Br$, $CO_2C_8H_{17}$, formyl, OH, $CH_2N(CH_2CH_2Cl)_2$, $CH(CH_3)OC(O)CH_3$, CH_2OH , $CH_2OC(O)CH_3$, $C(O)CH_3$, $C(O)C_6H_5$ and $C(O)NHCH_2CO_2CH_2CH_3$.

ix) ~~when R₁ is CH_3 and R₂ is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH(OH)C_6H_4-p-N(CH_3)_2$, $C(O)CH_2C(O)CH_3$, $CO_2CH_2C_6H_5$, CO_2CH_3 , $C(O)CH_2CH_2CH_3$, $C(O)CH_3$, $C(O)C_6H_4-p-OCH_3$, $C(O)C_6H_4-o-Br$, $C(O)C_6H_4-p-Cl$, $C(O)C_6H_4-o-Cl$, $C(O)CH_2C_6H_5$ and $C(O)C_6H_5$;~~

~~x) when R₂ is CH_2CH_3 then:~~

~~R₁ is not I and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2CH_2CH_3$;~~

~~R₁ is not CF_3 and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2CH_2CH_3$; and~~

~~R₁ is not Br and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2CH_2CH_3$;~~

xi) ~~when R₁ is OH and R₂ is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $C(O)C_6H_5$, $C(O)NH_2$ and $CO_2CH_2CH_3$;~~

xii) ~~when R₁ is H and R₂ is $C(CH_3)_3$ then $-[W]_n-X-[Y]_m-Z$ together is not $CO_2C(CH_3)_3$, $C(O)NHC(O)CH_3$ and $C(O)NH_2$;~~

xiii) ~~when R₁ is OH and R₂ is $CH_2CH_2CH_2CH_3$ then $-[W]_n-X-[Y]_m-Z$ together is not $C(O)C_6H_5$; and~~

~~xiv) when X is NR_3 then "n" is 1.~~

Claims 2-151 are cancelled.

152. (Currently Amended) The compound according to claim 1 wherein W is the straight or branched C₁₋₅ alkylene group optionally containing one double bond[],] or one triple bond ~~or carbonyl~~, wherein said C₁₋₅ alkylene group is optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.

153. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is selected from the group consisting of $-CH_2-$, $-CH_2CH_2-$, $-CH(CH_3)CH_2-$, $-CH_2CH(CH_3)-$,

~~-C(CH₃)₂CH₂-, -CH₂C(CH₃)₂-, -CH₂CH₂CH₂-, and -CH₂CH₂CH₂CH₂-, -CH₂C(O)-, C(O)CH₂-,~~
~~-CH(CH₃)C(O)-, C(O)CH(CH₃)-, -CH₂CH₂C(O)-, C(O)CH₂CH₂-, C(CH₃)₂C(O)-, C(O)C(CH₃)₂-,~~
~~-C(CH₃)₂CH₂C(O)-, C(O)CH₂C(CH₃)₂-, -CH₂C(O)CH₂-, -CH₂CH₂CH₂C(O)-, C(O)CH₂CH₂CH₂-,~~
~~-CH(CH₃)CH₂CH₂C(O)-, C(O)CH₂CH₂CH(CH₃)-, -CH₂CH₂C(O)CH₂-, -CH₂C(O)CH₂CH₂-,~~
~~CH=CHC(O)-, C(O)CH=CH-, C(CH₃)=CHC(O)-, and C(O)CH=C(CH₃)-, each optionally substituted~~
with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.

154. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is -CH(CH₃)-,
-CH(OCH₃)CH₂-, or -CH₂CH(OCH₃)-, each optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or
C₁₋₄ alkoxy.

155. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is selected from the
group consisting of -CH₂-, -CH(CH₃)-, -C(CH₃)₂-, -CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂CH(CH₃)-,
-C(CH₃)₂CH₂-, -CH₂C(CH₃)₂-, -CH(OCH₃)CH₂-, -CH₂CH(OCH₃)-, -CH₂CH₂CH₂-, and -
CH₂CH₂CH₂CH₂-, ~~-CH₂C(O)-, C(O)CH₂-, CH(CH₃)C(O)-, C(O)CH(CH₃)-, -CH₂CH₂C(O)-,~~
~~-C(O)CH₂CH₂-, C(CH₃)₂C(O)-, C(O)C(CH₃)₂-, C(CH₃)₂CH₂C(O)-, C(O)CH₂C(CH₃)₂-, -CH₂C(O)CH₂-,~~
~~-CH₂CH₂CH₂C(O)-, C(O)CH₂CH₂CH₂-, -CH(CH₃)CH₂CH₂C(O)-, C(O)CH₂CH₂CH(CH₃)-,~~
~~-CH₂CH₂C(O)CH₂-, -CH₂C(O)CH₂CH₂-, -CH=CHC(O)-, C(O)CH=CH-, C(CH₃)=CHC(O)-, and~~
~~-C(O)CH=C(CH₃)-.~~

156. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is -CH=CH-[[,]] or -
C≡C-, or -C(O)-.

157. (Previously Presented) The compound according to claim 1 wherein Y is the straight or branched
chain C₁₋₅ alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein
said C₁₋₅ alkylene group is optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.

158. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is selected from the
group consisting of -CH₂-, -CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂CH(CH₃)-, -C(CH₃)₂CH₂-, -CH₂C(CH₃)₂-, -
CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -C≡CCH₂-, -CH₂C≡C-, -CH₂C(O)-, -C(O)CH₂-,

-CH(CH₃)C(O)-, -C(O)CH(CH₃)-, -CH₂CH₂C(O)-, -C(O)CH₂CH₂-, -C(CH₃)₂CH₂C(O)-, -C(O)CH₂C(CH₃)₂-, -CH₂C(O)CH₂-, -CH₂CH₂CH₂C(O)-, -C(O)CH₂CH₂CH₂-, -CH(CH₃)CH₂CH₂C(O)-, -C(O)CH₂CH₂CH(CH₃)-, -CH₂CH₂C(O)CH₂-, -CH₂C(O)CH₂CH₂-, -CH=CHC(O)-, -C(O)CH=CH-, -C(CH₃)=CHC(O)-, and -C(O)CH=C(CH₃)-, each optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl or C₁₋₄ alkoxy.

159. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is selected from the group consisting of -CH₂-, -CH₂CH₂-, -CH(CH₃)CH₂-, -CH₂CH(CH₃)-, -C(CH₃)₂CH₂-, -CH₂C(CH₃)₂-, -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -C≡CCH₂-, -CH₂C≡C-, -CH₂C(O)-, -C(O)CH₂-, -CH(CH₃)C(O)-, -C(O)CH(CH₃)-, -CH₂CH₂C(O)-, -C(O)CH₂CH₂-, -C(CH₃)₂CH₂C(O)-, -C(O)CH₂C(CH₃)₂-, -CH₂C(O)CH₂-, -CH₂CH₂CH₂C(O)-, -C(O)CH₂CH₂CH₂-, -CH(CH₃)CH₂CH₂C(O)-, -C(O)CH₂CH₂CH(CH₃)-, -CH₂CH₂C(O)CH₂-, -CH₂C(O)CH₂CH₂-, -CH=CHC(O)-, -C(O)CH=CH-, -C(CH₃)=CHC(O)-, and -C(O)CH=C(CH₃)-.

160. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is -CH(CH₃)- optionally substituted with halogen, hydroxyl or C₁₋₄ alkoxy.

161. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is -CH(OCH₃)CH₂- or -CH₂CH(OCH₃)- optionally substituted with halogen, hydroxyl or C₁₋₄ alkyl.

162. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is -CH=CH- optionally substituted with C₁₋₄ alkyl or C₁₋₄ alkoxy.

163. (Currently Amended) The compound according to claim ~~1~~ 157 wherein Y is $-\text{C}(\text{CH}_3)_2-$, $-\text{C}\equiv\text{C}-$, $-\text{C}(\text{O})-$, $-\text{C}(\text{CH}_3)_2\text{C}(\text{O})-$, or $-\text{C}(\text{O})\text{C}(\text{CH}_3)_2-$.

164. (Previously Presented) The compound according to claim 1 wherein X is $-\text{NHC}(\text{O})-$ or $-\text{C}(\text{O})\text{NH}-$.

165. (Previously Presented) The compound according to claim 1 wherein X is $-\text{NH}-$ or $-\text{NCH}_3-$.

166. (Currently Amended) The compound according to claim 1 wherein X is selected from the group consisting of ~~$-\text{C}(\text{O})-$~~ , $-\text{CH}(\text{OH})-$, $-\text{C}(\text{NH})-$, $-\text{O}-$, $-\text{S}-$, $-\text{S}(\text{O})-$, or $-\text{S}(\text{O})_2-$.

167. (Previously Presented) The compound according to claim 1 wherein Z is H, halogen, or phenyl.

168. (Previously Presented) The compound according to claim 1 wherein Z is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{CF}_3$, $-\text{NHCH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{OCH}_3$ and $-\text{OCF}_3$.

169. (Previously Presented) The compound according to claim 1 wherein Z is heteroaryl optionally substituted with 1 to 3 substituents selected from the group consisting of $-\text{F}$, $-\text{Cl}$, $-\text{Br}$, $-\text{CF}_3$, $-\text{NHCH}_3$, $-\text{N}(\text{CH}_3)_2$, $-\text{CH}_3$, $-\text{CH}_2\text{CH}_3$, $-\text{OCH}_3$ and $-\text{OCF}_3$.

170. (Previously Presented) The compound according to claim 1 wherein R_1 is H.

171. (Cancelled)

172. (Previously Presented) The compound according to claim 1 wherein R_1 is halogen.

173. (Previously Presented) The compound according to claim 1 wherein R_1 is C_{1-4} alkyl.


174. (Previously Presented) The compound according to claim 1 wherein R_1 is C_{1-4} haloalkyl.

175. (Previously Presented) The compound according to claim 1 wherein R₂ is H.
176. (Previously Presented) The compound according to claim 1 wherein R₂ is C₁₋₈ alkyl.
177. (Currently Amended) The according to claim 1 selected from the group consisting of:
- 5-Ethylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;
 - 5-Ethanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;
 - 5-Ethanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;
 - 5-(2-Oxo-propoxymethyl)-1H-pyrazole-3-carboxylic acid;
 - 5-Prop-2-ynyloxymethyl-1H-pyrazole-3-carboxylic acid;
 - ~~5-Carbamoyl-1H-pyrazole-3-carboxylic acid;~~
 - 5-(1-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;
 - 5-(1-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;
 - 5-(1-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;
 - 5-(1,1-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;
 - ~~5-(2-Carboxy-1,1-dimethyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
 - 5-(1-Acetoxy-ethyl)-1H-pyrazole-3-carboxylic acid;
 - ~~5-(3-Hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(1-Chloro-3-hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(2-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(2-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(2-Carboxy-1-methyl-vinyl)-1H-pyrazole-3-carboxylic acid;~~
 - 5-Propylcarbamoylmethyl-1H-pyrazole-3-carboxylic acid;
 - ~~5-(2-Amino-vinyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(2-Amino-propyl)-1H-pyrazole-3-carboxylic acid;~~
 - 5-(2-Dimethylamino-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;
 - ~~5-(1-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(1-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(2-Hydroxy-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(3-Carboxy-1-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~
 - ~~5-(2-Carboxy-vinyl)-1H-pyrazole-3-carboxylic acid;~~

5-(2-Methoxy-vinyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Acetoxy-propyl)-1H-pyrazole-3-carboxylic acid;
~~5-Carbamoylmethyl-1H-pyrazole-3-carboxylic acid;~~
~~5-Hydroxymethyl-1H-pyrazole-3-carboxylic acid;~~
5-(2,2-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Imino-propyl)-1H-pyrazole-3-carboxylic acid;
~~5-(2-Amino-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-(Ethoxycarbonyl-fluoro-methyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-(1-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-Ethoxycarbonylmethyl-1H-pyrazole-3-carboxylic acid;~~
~~5-(2-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;
~~5-(1-Methoxycarbonyl-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-(1-Hydroxy-1-methoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-(3-Methoxycarbonyl-propyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-(2-Methoxycarbonyl-vinyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-Dimethylearbamoylmethyl-1H-pyrazole-3-carboxylic acid;~~
1H-Pyrazole-3,5-dicarboxylic acid;
5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid;
5-(2-Methoxy-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methoxy-propyl)-1H-pyrazole-3-carboxylic acid;
5-Methylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;
5-Methanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;
5-Methanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;
5-(2-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methylsulfanyl-propyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methanesulfinyl-propyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methanesulfonyl-propyl)-1H-pyrazole-3-carboxylic acid;
~~5-(2-Amino-ethyl)-1H-pyrazole-3-carboxylic acid;~~

5-(2-Methylamino-ethyl)-1H-pyrazole-3-carboxylic acid;
 5-(2-Dimethylamino-ethyl)-1H-pyrazole-3-carboxylic acid;
~~5-(2-Oxo-propyl)-1H-pyrazole-3-carboxylic acid;~~
~~5-(3-Oxo-butyl)-1H-pyrazole-3-carboxylic acid;~~
 5-(Benzylamino-methyl)-1H-pyrazole-3-carboxylic acid;
 5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;
 5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid; or
 5-(2,2-Diethoxy-ethyl)-1H-pyrazole-3-carboxylic acid; or
 a pharmaceutically acceptable salt, solvate or hydrate thereof.

178. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with at least one compound according to Formula (I):



wherein:

~~W and Y are independently~~ is a straight or branched chain C₁₋₅ alkylene group optionally containing one double bond ~~[[,]]~~ or one triple bond ~~or carbonyl~~, wherein said C₁₋₅ alkylene group is optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl, C₁₋₄ haloalkyl or C₁₋₄ alkoxy;

Y is a straight or branched chain C₁₋₅ alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C₁₋₅ alkylene group is optionally substituted with halogen, hydroxyl, C₁₋₄ alkyl, C₁₋₄ haloalkyl or C₁₋₄ alkoxy;

X is -NR₃C(O)-, -C(O)NR₃, -NR₃S(O)₂-, -S(O)₂NR₃-,
 -NR₃C(O)NR₄-, -NR₃C(O)O-, -OC(O)NR₃-, -NR₃-, ~~-C(O)-~~, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or -S(O)₂-;

R₃ and R₄ are independently H, C₁₋₄ alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C₁₋₄

haloalkyl, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C₁₋₄ haloalkyl, amino, C₁₋₄ alkylamino, di-C₁₋₄-alkylamino, C₁₋₄ alkyl, C₁₋₄ alkoxy, C₂₋₄ alkenyl, C₂₋₄ alkynyl, C₁₋₄ haloalkoxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulfinyl, C₁₋₄ alkylsulfonyl, C₁₋₄ haloalkylthio, C₁₋₄ haloalkylsulfinyl and C₁₋₄ haloalkylsulfonyl;

R₁ is H, ~~hydroxyl~~, halogen, C₁₋₄ alkyl or C₁₋₄ haloalkyl;

R₂ is H or C₁₋₈ alkyl and

"n" and "m" are each ~~independently 0 or 1~~; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

~~provided that when X is -NR₃, then "n" is 1.~~

179. (Previously Presented) A method for prophylaxis or treatment of a metabolic-related disorder in an individual in need of said prophylaxis or treatment comprising administering to the individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 178.
180. (Previously Presented) The method according to claim 179 wherein the metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.
181. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
182. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia.

183. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is atherosclerosis.
184. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is coronary heart disease.
185. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is insulin resistance.
186. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is type 2 diabetes.
187. (Previously Presented) The method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.